The One Stock That Could Make You a Marijuana Millionaire

The One Stock That Could Make
You a Marijuana Millionaire

How FDA approval and a pipeline of breakthrough marijuana
medicines are about to send this stock soaring another 1,303%


Photo: Hilary KramerHilary Kramer, whose GameChangers advisory service has delivered over 100 double-digit winners since 2011, has identified another breakout winner for immediate purchase.

As you’ll read here in this special BUY ALERT, this $3 billion Mari-Pharma company is not only months away from receiving the world’s first FDA-approved marijuana medicine but also has over 60 patents that could give it a monopoly-like position for virtually every cannabis-based medicine for treating or curing everything from Alzheimer’s, Parkinson’s, and multiple sclerosis to numerous forms of cancer.

If you can get in now, before it receives FDA approval, you could see a $10,000 investment and grow into $1 million or more over the next 10-20 years.

Read on for the full story…

Dear Investor,

If you don’t take a small position in this marijuana stock, you’ll regret it for the rest of your life.

Over the past five years, this company’s stock has risen 1,303% and is set to repeat these great gains over the next five.

That’s a big claim, I know.

But not when you understand how this $3 billion Mari-Pharma company:

  1. Developed the world’s first prescription marijuana medicine that’s now approved for treatment in 29 countries outside the United States.
  2. Possesses a pipeline of eight additional clinical-stage cannabinoid product candidates, many of which have been granted Orphan Drug Designation status by the FDA.
  3. Locked up the patent rights to a number of cannabis-derived medicines under development, including treatments for Alzheimer’s disease, breast cancer, colon cancer, diabetes, multiple sclerosis, Parkinson’s disease, prostate cancer, and schizophrenia and…
  4. May be months away from bringing the USA’s first FDA-approved cannabis-formulated treatment for epilepsy to the market.

This is why Goldman Sachs not only rates the company a BUY, but goes one step further, writing that it’s “set to fly high.”

The reason is simple.

That’s because they see, as we do, the company using its vast patent rights to shape the future of medical cannabis no differently than Tesla has shaped the future for electric cars.

When you look at the company’s patent that covers the prevention and treatment of neurodegenerative diseases, you’ll understand what I mean.

That’s because the company’s patented cannabis extraction method not only covers all the active components of cannabis, including THC, CBD, terpenes, sterols, triglycerides, alkanes, and flavonoids…

… but also allows it to claim ownership of cannabis as a drug in the prevention and treatment of Alzheimer’s disease, Parkinson’s disease and multiple sclerosis.

Do you realize what this means?

This patent could give it a monopoly-like position for virtually every cannabis-based medicine for treating or curing Alzheimer’s, Parkinson’s and multiple sclerosis.

When you consider that the Alzheimer’s, Parkinson’s and multiple sclerosis treatment markets are expected to exceed $40 billion over the next five years, the investment potential gives me goose bumps.

That’s only one of the patents the company has received for what we call its Mari-Pharma discoveries. The one it filed in 2013 could give the company a monopoly in the treatment of prostate cancer, breast cancer and colon cancer as well.

When you consider that the cancer treatment market is expected to reach $150 billion a year by 2020, you can understand why I’ve been telling my readers that this one stock, when held for the long term, could make them marijuana millionaires.

Your Timing Here is Perfect

You couldn’t ask for a better time to add this company to your holdings, as it may be just months away from receiving FDA approval for its breakthrough cannabis-formulated epilepsy drug.

When I say breakthrough, I mean it.

Clinical testing found that this new epilepsy drug reduces seizures by 54% and without the side effects of fatigue and nausea that are associated with current medical treatments.

This is why one well-respected industry analyst projects that this company’s cannabis-formulated drug could generate peak annual sales of around $3 billion.

At that rate, the stock could see its earnings jump a whopping 2,900% in the first year alone, turning the company from a $3 billion operation to one with a market cap of $30 billion.

While I can’t tell you the exact day that it will win FDA approval for its cannabis-based epilepsy treatment, I can tell you this: now is not the time to take a wait-and-see approach.

With Wall Street expecting the company to generate 1,317% sales growth next year and two top analysts raising the company’s earnings for both this year and the next, word may be beginning to leak out.

That’s the whole reason I sent you this special alert, to show you just how big the potential is for making money here.

When I say BIG, I mean it.

You see, this would be the first company anywhere in the world to obtain FDA approval for cannabis-formulated epilepsy medicine. The company has finished its Phase Three trials and is simply waiting for the decision to come by the end of the year.

When this drug is approved, it will not only open the door to other FDA-approved marijuana medicines but also could give this company a monopoly on most of them—thanks to the patented formulary processes the company has been developing over the past decade.

Which is why Goldman Sachs writes the company is “set to fly.”

Here’s the best part.

Because eight states have legalized recreational pot use, nobody is talking about the medical use. It's completely off the radar. The only reason I know about it is because I've been a Wall Street insider for the past 30 years.

Because I’m in direct contact with the key players on Wall Street, I can tell you with unparalleled certainty that you may never see this kind of opportunity in your life again.
I guarantee the returns will knock your socks off.

Welcome to GameChangers

My name is Hilary Kramer, and I’ve been bringing my readers gems like this ahead of Wall Street since 2011.

If my name sounds familiar it’s because you’ve seen me on CNBC, CNN or the Fox News Channel, read my market insights in the Wall Street Journal, the New York Post, Bloomberg, or Forbes, or read one of my best-selling investment books, Ahead of the Curveor The Little Book of Big Profits from Small Stocks.

If there’s just one reason why the financial media seeks me out, it’s because my forecasts and stock picks are amazingly accurate—handing my readers more than 100 double-digit winners since 2011.

When these interviewers ask me the secret to my success, my answer is simple: We invest in undiscovered gems that are turning whole industries upside down. Game-changers, if you will, that are changing the way we work, live and invest.

Radical innovators like …

  • Apple, which has not only revolutionized the music, tablet and smartphone industries but has rewarded investors with 973% gains since 2007.
  • Amazon, whose online sales disrupted the retail business, growing 1,989% in the past 10 years.
  • Priceline, whose online travel service changed the way the world travels, rising 2,913% since 2007.
  • Tesla, which single-handedly revolutionized the electric car market, handing investors 1,233% over the same time period.
  • Netflix, whose online streaming technology put the video rental industry out of business, with 4,149% gains since 2007.

This is why I can tell you with unmatched certainty, our newest recommendation falls into that same category.

What makes me think so?

You need only look at the rapid pace of marijuana legalization in the U.S. Already 28 states allow medical marijuana. When the final tally comes in, that amounts to nearly $7 billion a year in sales. Industry experts forecast medical marijuana sales will hit $22 billion by 2020—for a 214% increase in three years.

In my years of investing, I’ve never seen a sector with stronger, faster growth potential.

And it’s all because FDA-approved medical marijuana will give doctors a powerful new weapon that could potentially be more effective than the current treatments for medical conditions including glaucoma, anxiety, arthritis, lupus, Crohn’s disease, PTSD, stroke, concussions, trauma, and more.

But won’t legal recreational pot undermine the medical marijuana industry?

No. The opposite is true.

You see, recreational pot is like a street drug designed just to get you high.

However, medical forms of the drug synthesize compounds found in marijuana to treat a number of different conditions. The best comparison I can offer is OxyContin, which your doctor prescribes for pain and which comes from the same opium poppy as heroin.

Most Americans don’t know this, but of the 150 top prescription drugs, 74% come from plants like marijuana.

According to the National Cancer Institute, 70% of the drugs introduced in the United States over the past 25 years are derived from natural sources.

In fact, plant-derived anti-cancer drugs such as Taxol, which is derived from the bark of the Pacific yew tree and is credited for saving at least 30,000 lives per year in the United States, are credited with $1.6 billion in annual sales.

That’s what makes our newest recommendation such a game-changer. Once it receives FDA approval, this first drug treatment could overturn the entire medical marijuana industry—giving the pharmaceutical industry the green light to enter the market, which is expected to be worth $22 billion in three years.

As a result, medical marijuana dispensaries (where you now find a witch’s brew of untested treatments) would give way to real medicines that have passed FDA testing and that you could pick up at your local CVS or Walgreens and even have covered by insurance.

With scientists finding that compounds contained in marijuana could have a big impact on AIDS/HIV, Alzheimer’s disease, arthritis, asthma, cancer, chronic pain, Crohn’s disease, epilepsy, glaucoma, and multiple sclerosis, my hands itch in anticipation of the profits that are headed our way—especially when you consider these treatment markets are worth more than $150 billion!

This Is Why the Big Institutional
Investors Are Loading Up

Especially now that Goldman Sachs has given the company such a glowing BUY rating.

Just look:

Top Institutional Holders

Holder Shares Date Reported % Out Value
Capital Research Global Investors 3,017,604 Dec. 30, 2016 11.99% 337,217,247
Scopia Capital Management LP 2,084,567 Dec. 30, 2016 8.28% 232,950,362
Prudential PLC 2,050,212 Dec. 30, 2016 8.14% 229,111,191
FMR, LLC 1,715,265 Dec. 30, 2016 6.81% 191,680,863
Deerfield management 928,192 Dec. 30, 2016 3.69% 103,725,456
Viking Global Investors, L.P. 910,831 Dec. 30, 2016 3.62% 101,785,364
Bank of America Corporation 656,291 Dec. 30, 2016 2.61% 73,340,519
JANUS CAPITAL MANAGEMENT, LLC 651,482 Dec. 30, 2016 2.59% 72,803,113
Capital World Investors 635,800 Dec. 30, 2016 2.59% 71,050,650
Price (T. Rowe) Associates Inc 466,894 Dec. 30, 2016 1.85% 52,175,404

Together they own millions of shares worth over $1 billion. This rush to own this company hasn’t been lost on the mutual fund managers either.

Holder Shares Date Reported % Out Value
Smallcap World Fund 1,976,400 Sep. 29, 2016 7.85% 262,327,564
New Economy Fund (The) 1,114,054 Sep. 29, 2016 4.43% 147,868,382
Fidelity Select Portfolios — Biotechnology 1,069,498 Oct. 30, 2016 4.25% 125,548,369
American Funds insurance Ser-Global Small Capitalization Fund 687,950 Sep. 29, 2016 2.73% 91,311,600
Fidelity Advisor Biotechnology Fund 281,567 Oct. 30, 2016 1.12% 33,053,149
Federated Kaufmann Fund 280,000 Jul. 30, 2016 1.11% 36,409,600
Price (T. Rowe) Health Sciences Fund 262,271 Sep. 29, 2016 1.04% 34,811,228
Janus Global Life Sciences Fund 248,766 Dec. 30, 2016 0.99% 27,799,600
iShares NASDAQ Biotechnology ETF 207,274 Sep. 29, 2016 0.82% 27,511,477
Advantage Funds, Inc. — Dreyfus Opportunistic Small Cap Fund 179,704 Sep. 29, 2016 0.71% 23,852,111

They own nearly as many shares for the same reason. And it’s all because this company is not only pre-positioned to dominate the medical marijuana industry.

That’s why I suggest you get in now, too, as my research shows…

This Company’s Profits Could Soar 1,000%

And that’s from just the sales of their one epilepsy drug I mentioned earlier.

With the company already possessing 60 patents directed to marijuana extracts, extraction technology, pharmaceutical formulations, drug delivery, and the therapeutic uses of cannabinoids, this company could ultimately become the Gilead of medical marijuana.

If Gilead’s 9,915% profits over the past 20 years are any indication of the profit opportunity that’s at hand, you’d be foolish not to take a position in this $3 billion Mari-Pharma juggernaut.

Of course, I can't promise this company will deliver 9,915% like Gilead has. Few companies ever do. However, if it were to jump just 1/10th over the next 20 years, I guarantee you’ll be smiling all the way to the bank.

This is why shrewd insiders and institutions like Capital Research Global Investors, Bank of America, and FMR LLC are all backing up the truck here.

The reason is simple.

These big-time insiders and savvy money managers know, better than anyone, how this company’s advanced research and patents could shape the future of medical marijuana…and the big money this company is set to make.

That’s why, together, they’re all in to the tune of over $1 billion.

Text Box: The One Stock That Could Make You a Marijuana Millionaire By Hilary Kramer, editor Game Changers But time is running out for you to get in on the ground floor.
The company could receive FDA approval of its epilepsy drug at any time. Once it does, you’re going to see its stock price jump, as Goldman Sachs puts it, “high.”

To make sure you don’t miss this, I've put together a special report titled The One Stock That Could Make You a Marijuana Millionaire that will give you a panoramic overview of the kind of wealth this company’s patents and cannabis-based medicines could generate, including its name and stock symbol, and why this long-term investment would make a great addition to your retirement account.

The report is yours absolutely free. All I ask in return is that you give my GameChangers investment research advisory service a risk-free try.

If you’ve never seen GameChangers before, it’s a one-of-a-kind investment advisory that focuses on finding companies that are turning industries on their heads—companies that have the potential to be the next Apple, Amazon, Netflix, or Tesla.

Companies with BETTER IDEAS…ADVANCED TECHNOLOGIES…and/or BIOTECH BREAKTHROUGHS that have graduated from the garage but are still a long way from inclusion in the big indexes.

Those are exactly the opportunities we target—companies that are not only disrupting their industry but are also light-years ahead of their closest competition.

That’s why I’m hoping you’ll add our newest recommendation to your holdings now. Because once the word gets out and the herd rushes in and starts buying, you could miss the company’s next 1,303% rise.

Frankly, that’s our goal: to get you into these game-changing companies early, before Wall Street takes notice and the big money is made. This is how our readers have grabbed more than 100 double-digit winners since 2011.

As proud as I am of these wins, I simply can’t stress this enough: they pale in comparison to the profits this $3 billion Mari-Pharma company will make over the next decade.

The reason is simple:

  1. It’s just a matter of time before the FDA approves this company’s epilepsy treatment and signals to the world that medical marijuana isn’t just a fad and Big Pharma decides to come in.
  2. Its 60 patents throughout the industry will give it a monopoly-like position for years in a treatment sector that’s worth more than $190 billion.

The One Stock That Could Make You a Marijuana Millionaire will bring you all the details and also get you in on the ground floor of what could be the greatest stock-buying opportunity of the 21st century.

Again, the report is yours absolutely free…just for giving GameChangers a try.

In addition, your free report will lay the foundation for every new game-changer I will bring you in the months ahead…

…along with our philosophy of investing in game-changing companies and breakthrough technologies that are turning whole industries upside down and richly rewarding investors along the way.

In each monthly issue, we will guide you to the most promising game-changer opportunities before they enter their hyper-growth stage…before they become front-page news…and before the big money is made.

And just as you’ve seen here, we’ll not only break down their technologies, revenue streams, and profit potential but also crunch the numbers and dig into the market size and growth potential.

And we’ll show you why each one could become the next Apple, which has grown more than 1,989% over the past 10 years… or the next Amazon, which has provided 2,913% gains over the same time period… or the next Netflix, which handed investors a 4,149% payday.

The moment you agree to give us a try, you'll get immediate access to the special report The One Stock That Could Make You a Marijuana Millionaire…along with our complete portfolio of game-changing recommendations, which includes:

  • The data-driven marketing company whose proprietary cloud-based marketing systems could double investors’ money again in 2017.
  • The home security juggernaut that’s reinvented not only how to remotely monitor and manage security systems but also how to connect everything from your lights, thermostat, shades, and solar system directly to your smartphone.
  • The Internet security firm whose 100% operational accuracy could make all websites virtually hack-proof.
  • The wealth management company whose behind-the-scenes technology is already making 200 other wealth management companies wealthier.
  • The breakthrough medical devices used for treating heart disease that could hand you $10 to $1 gains over the next 10 years.
  • The Uber of business payments whose proprietary technologies and growing global network could bypass MasterCard’s 2359% gains to date.

Together, they offer you the opportunity to get in on the ground floor of these radical innovators right at the beginning of their hyper-growth stage where their potential rewards are enormous.

This is how we’ve handed our readers more than 100 double-digit winners since 2011—all by spotting the trends early and identifying these radical innovators light-years ahead of Wall Street.

The thanks I have received from my readers over the years has been truly humbling. Rosemary K. wrote me personally to say…

“I’m up a total of $21,489 in less than one year! Thanks for your help in making money for me. Keep up the great work!”

New member D. Murphy is equally glad he joined.

“I have only been with GameChangers for a short time, but am already up approximately 32% on the stocks I’m in.”

Bill M. wrote to say that he used the money from one trade to book a cruise… while Larry L. used the profits from one trade to pay for a trip to Europe.

Longtime subscriber J. Gaydos also wrote me to say how our advanced forecasts and timely recommendations have helped him secure his family’s future.

“I just want to say THANK YOU all for helping me with your investments ideas over the past few years. I have been able to increase my wealth as I near retirement.”

Today’s buy alert offers you a sneak preview of the kind of complete analysis and recommendations we’ll bring you when you join us.

Here’s what you’ll receive the
moment you become a member

  • First, you’ll receive a welcome email with your private login and password to our VIP GameChangers subscribers-only website, where you’ll find our current portfolio, monthly issue, and archives of all prior issues, updates, alerts, and special reports.
  • Once you’ve logged in you’ll gain instant access to your free copy of The One Stock That Could Make You a Marijuana Millionaire that includes my full research on this incredible opportunity, including my buy, hold, and sell prices.
  • Then you’ll begin to receive one to three winning picks every month sent directly to you via email—all ground-floor opportunities (just like The One Stock That Could Make You a Marijuana Millionaire profiled here) that are not only disrupting their industries but also light-years ahead of their closest competition.
  • You’ll also receive weekly updates on our recommendations, so you can stay a step ahead of Wall Street.
  • Because the markets change daily, I will send you a Flash Alert via email or text whenever breaking news impacts any of our recommendations, along with complete buy, hold, or sell instructions to protect your wealth and maximize your profits.

For the past six years, I’ve helped tens of thousands of Americans like you invest and grow rich in many of the most profitable stocks of our time. All of them got started by accepting a risk-free copy of my most recent research report…along with a risk-free membership.

On that fair-and-square basis, GameChangers has become one of the most profitable investment advisories in America. Judging by our 100+ double-digit winners over the past six years, our advice is paying off in droves.

I’m betting that you’ll see similar results. Our 100% money-back guarantee promises just that.

A Special Price for Regular Investors Who Want
to Own the Next Apple, Amazon, Netflix, or Tesla

My mission here at GameChangers has been and always will be to help regular investors like you get in on the ground floor of Wall Street’s most profitable opportunities. That’s why I launched GameChangers in the first place.

And while my colleagues have told me that I could easily charge $10,000 a year for GameChangers given my track record, that would go against my goal of helping regular investors like you get in on the ground floor of these early-stage companies that make insider and institutional investors multimillionaires.

That’s why I’ve made it possible for new subscribers to join me at a shockingly low 27 cents a day—that comes to $99 a year and $400 off the regular pricebut this special discount comes with just one catch.

You see, GameChangers is for investors who truly want to own the next Apple, the next Amazon, or the next Tesla and are willing to act on my recommendations.

If you are willing to invest in my recommendations, then you will enjoy the great profits my advisory has brought others and you will never invest any other way.

However, if you can’t take the action required to accept your free copy of The One Stock That Could Make You a Marijuana Millionaire or take advantage of my $400 discount, chances are you won’t be able to take the action necessary to profit when I instruct you to purchase or sell these opportunities, and I would be remiss in accepting you as a new member.

That’s why you’ll need to decide TODAY to grab the 27-cents-a-day price.

The reason I have set this up this way is because in investing, as in life, you simply don’t get a second chance. If you missed out on grabbing Apple, Amazon or Tesla and the life-changing gains they would have handed you, then you know what I mean.

If you have the foresight to say yes today, all you need to do is click the “Join Now” button below and I’ll send you your FREE copy of The One Stock That Could Make You a Marijuana Millionaire, lock in your $400 discount, and begin your 27-cents-a-day trial subscription.

I’ve made it so easy, convenient and risk-free for you to give GameChangers a free try, there’s really no way you can lose here.

That’s because…

If You’re Not 100% Delighted,
You Get Every Penny Back

Text Box: The One Stock That Could Make You a Marijuana Millionaire By Hilary Kramer, editor Game Changers I hope that you have enjoyed reading about The One Stock That Could Make You a Marijuana Millionaire and will consider investing in it. It’s truly the real deal and a sneak preview of the kind of recommendations we will bring you when you join us.

Our ultimate goal is to win you as a member for life, so we will return your money if for any reason we fail to meet your expectations right up to the last day of your membership.

That’s why you can join us today with complete confidence knowing that you will always receive a 100% refund of the full balance of your membership, at any time.

But you’ll have to make your decision today.

The opportunity to invest in The One Stock That Could Make You a Marijuana Millionaire, before its price really takes off, may not last long.

So if you want to get in on the ground floor and profit with us, then I urge you to accept my guarantee and savings offer today without hesitation.

BOTTOM LINE: The early birds really do make the most money when it comes to investing.

Just or on the button below and you can be one of them.

When you do, you’ll go to a secure order form where you can review everything we’ve talked about, download your free report, and begin your trial subscription.

In closing, I want to thank you for learning today about the big money our top marijuana stock will make you,and I look forward to welcoming you as a new subscriber.



Hilary Kramer
Editor, GameChangers

P.S. I simply can’t stress this enough:

Once this $3 billion company gets FDA approval for its epilepsy medicine, it’s going to leapfrog to the forefront of the Mari-Pharma industry—all thanks to its 60 patents that for treating everything from Alzheimer’s to cancer to post traumatic stress.

To me, this is an investment that’s destined to make millionaires out of many early shareholders.

Click the button below to download your free copy of The One Stock that Will Make You a Marijuana Millionaire and you can be one of them.



We hope this timely investing advice is valuable to you. As you know the markets move fast and conditions change frequently. So please check the current issue for the most recent advice.

To make sure you received the most recent updates, please tell us if your email has changed by visiting here:

If you would rather not receive actionable investing advice from InvestorPlace Media experts, you can let us know by visiting

We will honor your request within 7-10 days.

InvestorPlace Media, LLC.
9201 Corporate Blvd, Suite 200
Rockville, MD 20850

If you have any questions call 1-800-219-8592 and use priority code A1G199.

Copyright © 2017 InvestorPlace Media, LLC.

All rights reserved.


Please note that we cannot be liable for any missed bulletins caused by overzealous spam filters. To ensure that you continue to receive this valuable part of your service please take a moment to add ([email protected]) to your address book. for instructions:[email protected]


< href="" rel="stylesheet" type="text/css"/>

Related Post

Blue Horseshoe Stocks: BVTK Pops Again & More

Blue Horseshoe Stocks: INMG New Highs & More